Compass Therapeutics Q1 2024 Earnings Report $3.90 +0.40 (+11.43%) As of 02/10/2025 04:00 PM Eastern Earnings HistoryForecast Compass Therapeutics EPS ResultsActual EPS-$0.08Consensus EPS -$0.11Beat/MissBeat by +$0.03One Year Ago EPSN/ACompass Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACompass Therapeutics Announcement DetailsQuarterQ1 2024Date5/13/2024TimeN/AConference Call ResourcesPress ReleaseCMPX Earnings HistoryPowered by Compass Therapeutics Earnings HeadlinesWhy Compass Therapeutics Inc (CMPX) Is Skyrocketing So Far In 2025February 4, 2025 | msn.comCompass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | markets.businessinsider.comOvernight phenomenon = Daily payout opportunities?Thanks to a new set of backtested data… And an intriguing overnight market phenomenon that originated in the 1990s… I've enhanced my "Automated Options" strategy to achieve results much faster. Folks could have pocketed $4,878 in overnight gains that week.February 11, 2025 | ProsperityPub (Ad)Compass Therapeutics stock hits 52-week high at $2.68January 16, 2025 | msn.comCompass Therapeutics: Strategic Advancements and Promising Pipeline Justify Buy RatingJanuary 9, 2025 | markets.businessinsider.comCompass Therapeutics: Strong Growth Potential Bolstered by Upcoming Milestones and Strategic FocusJanuary 8, 2025 | markets.businessinsider.comSee More Compass Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Compass Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compass Therapeutics and other key companies, straight to your email. Email Address About Compass TherapeuticsCompass Therapeutics (NASDAQ:CMPX), a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.View Compass Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead?Earnings Miss? Amgen’s Dividend Still a Bright SpotPalantir Stock Surges After Blockbuster Earnings: What's Next?Atlassian: Upside Still in Play After Impressive Earnings SpikeWhy Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market Test Upcoming Earnings BP (2/11/2025)Energy Transfer (2/11/2025)Shopify (2/11/2025)AppLovin (2/12/2025)Cisco Systems (2/12/2025)Equinix (2/12/2025)Trade Desk (2/12/2025)Sony Group (2/12/2025)Williams Companies (2/12/2025)Applied Materials (2/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
